Medtronic’s (NYSE: MDT) growth efforts and investments in medical technology innovation are starting to pay off. The company's pulsed field ablation (PFA) technology is a key growth driver, strengthening both its cardiac segment and overall business expansion. However, the Q3 results were underwhelming relative to the consensus forecasts reported by MarketBeat, which means the stock price turnaround will take longer than initially indicated. The bad news is that new highs are unlikely until later in the year. The good news is that investors have more time to build their positions while the stock is trading near long-term lows.
